SCHEMBL3014116

SCHEMBL3014116

Cc1ccc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.43
ALDH3A1 P30838 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
LMNA P02545 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
USP2 O75604 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
THRB P10828 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
CNR1 P21554 1/20 0.39
HTT P42858 1/20 0.39
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015983 0.93 LPAR1 (0.42) MAPTALDH1A1L3MBTL1LMNANPSR1
SCHEMBL3002483 0.91 ALDH1A1 (0.41) MAPTALDH1A1L3MBTL1LMNARAB9A
SCHEMBL3007799 0.91 ALDH1A1 (0.43) MAPTALDH1A1L3MBTL1LMNARAB9A
SCHEMBL3012559 0.90 MAPT (0.49) MAPTALDH1A1TSHRLMNANPSR1
SCHEMBL3004102 0.90 MAPT (0.44) MAPTALDH1A1ALDH3A1L3MBTL1TSHR
SCHEMBL3014113 0.89 ALDH1A1 (0.46) MAPTALDH1A1L3MBTL1TSHRLMNA
SCHEMBL3019609 0.89 MAPT (0.45) MAPTALDH1A1ALDH3A1L3MBTL1TSHR
SCHEMBL3010663 0.89 ALDH1A1 (0.46) MAPTALDH1A1L3MBTL1TSHRLMNA
SCHEMBL2998623 0.88 MAPT (0.37) MAPTALDH1A1ALDH3A1L3MBTL1TSHR
SCHEMBL3018177 0.88 MAPT (0.44) MAPTALDH1A1ALDH3A1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885ALDH3A1 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.